

**Table S1 Laboratory Findings**


	Results before treatment	Results after 6 months' treatment	Reference Range
White Blood Cell Count, 10 <sup>9</sup> /L	7.34	5.23	3.50-9.50
Hemoglobin, g/L	62	101	110-150
Platelet, 10 <sup>9</sup> /L	78	110	100-350
Proteinuria, g/d	1.85 <sup>1</sup>	0.39	0.00-0.20
Creatine, mg/dl	7.2	0.6	0.5-1.0
Urea, mg/dl	155.5	11.3	7.8-20.0
K, mmol/L	6.1	3.8	3.5-5.5
Albumin, g/L	25	35	35-52
Alkaline Phosphatase, U/L	254	55	50-135
Gamma-glutamyl transpeptidase, U/L	261	62	7-45
Alanine Aminotransferase, U/L	30	33	7-40
Aspartate Aminotransferase, U/L	15	20	13-35
Total Bilirubin, μmol/L	21.9	10.2	5.1-22.2
Immunoglobulin G, g/L	14.93	3.37	7.00-17.00
Immunoglobulin A, g/L	1.38	0.34	0.70-4.00
Immunoglobulin M, g/L	0.70	0.30	0.40-2.30
Complement 3, g/L	1.069	1.213	0.730-1.460
Complement 4, g/L	0.391	0.363	0.100-0.400
Prothrombin Time, s	27.7	11.0	10.4-12.6
Activated Partial Thromboplastin Time, s	44.3	22.5	23.3-32.5
Fibrinogen, g/L	6.87	2.65	1.80-3.50
International Normalized Ratio	2.52	0.94	0.86-1.14
D-dimer, mg/L FEU	14.00	0.75	0-0.55
Erythrocyte Sedimentation Rate, mm/h	>140	20	0-20
Hyper sensitive C-Reactive Protein, mg/L	249.27	1.93	<3.00
Vascular Endothelial Growth Factor, pg/ml	6172	266 <sup>2</sup>	<600
Interlukin-6, pg/ml	6.7	2.0	<5.9
Interlukin-8, pg/ml	72	22	<62
Interlukin-10, pg/ml	14.8	5.0	<9.1
Tumor Necrosis Factor-α, pg/ml	7.2	6.2	<8.1

<sup>1</sup>This is the result right after the patient recovered from auric renal failure.

<sup>2</sup>This is the result on June. 17<sup>th</sup>, about 2 months after the initiation of BCD treatment.


**Table S2 This patient is consistent with all the Proposed Diagnostic Criteria of TAFRO**

<b>1. Histopathological criteria</b>	
• Compatible with the pathological findings of lymph nodes as TAFRO-iMCD	√
• Negative LANA-1 for HHV8	√
<b>2. Major criteria: 3 of 5 TAFRO symptoms</b>	
I. Thrombocytopenia	√
II. Anasarca	√
III. Fever	√
IV. Reticulin fibrosis	√
V. Organomegaly	√
Absence of hypergammaglobulinemia	√
Small volume lymphadenopathy	√
<b>3. One or more of the minor criteria</b>	
Hyperplasia/normoplasia of megakaryocytes in bone marrow	√
High serum level of ALP without markedly elevated serum transaminase	√



**Figure S1 The patient developed bowel obstruction after relapse of ascites**

In late February, the patient experienced a relapse of ascites, leading to bowel obstruction, right after we tapered the steroids to Prednisone 70mg/d. She finally recovered from this condition after supportive treatment including drainage of over 6 liters ascites and around 10 days of methylprednisolone 60mg/d.



**Figure S2 Lymph anode biopsy showed Castleman Disease (Hyaline-vascular type)**

The H&E staining showed prominent atrophic germinal center in lymphoid follicle accompanied by rearrangement of lymphatic cells around mantle zone, showing “onion skin like” pattern. Blood vessel hyperplasia and hyalinosis of vascular wall were also observed. These findings were consistent with hyaline-vascular type Castleman Disease.